Head to head
Mazdutide against Tirzepatide
Two dual agonists with different second receptors, one approved in China and one approved in the United States and Europe. No trial has put them against each other.
Column A
MazdutideMazdutide (GLP-1 / glucagon dual agonist)
A GLP-1 and glucagon receptor dual agonist approved in China in 2025 for obesity and type 2 diabetes, the first of its class approved anywhere, and not approved by the FDA.
Column B
TirzepatideTirzepatide (dual GIP/GLP-1 receptor agonist)
A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists.
Side by side, on the facts we can check
| Attribute | Mazdutide | Tirzepatide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Approved in China (2025) for obesity and type 2 diabetes; investigational elsewhere | FDA-approved (Mounjaro for T2D and, from August 2026, to reduce major cardiovascular events in T2D; Zepbound for weight management and sleep apnea) |
| Half-life | ~5-7 days | ~5 days |
| Molecular weight | ~4,800 Da | 4,813.5 Da |
| Mechanism | Agonizes GLP-1 and glucagon receptors to reduce appetite and improve glucose control while increasing energy expenditure. | Simultaneously activates GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, reducing glucagon, delaying gastric emptying, and reducing appetite. The GIP component is thought to add complementary metabolic effects. |
| Human studies cited | 2 | 4 |
| Legal status, US | Not approved | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Mazdutide and Tirzepatide?
Mazdutide: A GLP-1 and glucagon receptor dual agonist approved in China in 2025 for obesity and type 2 diabetes, the first of its class approved anywhere, and not approved by the FDA. Tirzepatide: A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists.
Which has stronger research evidence, Mazdutide or Tirzepatide?
This database does not grade compounds. It counts what was run in people: 2 of the 3 studies cited on the Mazdutide profile were human work, against 4 of 4 for Tirzepatide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Mazdutide and Tirzepatide FDA-approved?
Mazdutide: Approved in China (2025) for obesity and type 2 diabetes; investigational elsewhere. Tirzepatide: FDA-approved (Mounjaro for T2D and, from August 2026, to reduce major cardiovascular events in T2D; Zepbound for weight management and sleep apnea).
Related posts
Blog articles that cover Mazdutide or Tirzepatide, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
- Metabolic / Sep 8, 2026 / 9 minMariTide (Maridebart Cafraglutide): The Once-Monthly GLP-1 Agonist and GIP Blocker, Explained
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.